Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10892131 | 1.00 | TDP1 (0.52) | TDP1SMN1; SMN2SLC22A6GPR84CHRM1 | |
| SCHEMBL9782163 | 1.00 | TDP1 (0.52) | TDP1SMN1; SMN2SLC22A6GPR84CHRM1 | |
| SCHEMBL2956099 | 0.82 | TDP1 (0.68) | TDP1SMN1; SMN2SLC22A6MAPTGABRR1 | |
| SCHEMBL687714 | 0.82 | TDP1 (0.42) | TDP1GPR84CHRM1AKR1A1CHRM3 | |
| SCHEMBL3837519 | 0.82 | TDP1 (0.42) | TDP1GPR84CHRM1AKR1A1CHRM3 | |
| SCHEMBL28035406 | 0.81 | TDP1 (0.59) | TDP1SMN1; SMN2SLC22A6GPR84MAPT | |
| SCHEMBL3245749 | 0.80 | TDP1 (0.74) | TDP1SMN1; SMN2SLC22A6GPR84CHRM1 | |
| SCHEMBL1548356 | 0.79 | MEN1 (0.36) | TDP1SMN1; SMN2SLC22A6GPR84LMNA | |
| SCHEMBL3073651 | 0.78 | PDE4A (0.44) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL1895730 | 0.78 | PDE4A (0.44) | TDP1CHRM1AKR1A1CHRM3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2172471-B1 | A process for preparing intermediates of HMG-CoA reductase inhibitors | TEVA PHARMA (IL) | 2013-03-27 | — | — | EP | disclosed |
| US-7964748-B2 | Process for preparing intermediates of HMG-CoA reductase inhibitors | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2011-06-21 | — | — | US | disclosed |
| US-20100160663-A1 | PROCESS FOR PREPARING INTERMEDIATES OF HMG-CoA REDUCTASE INHIBITORS | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2010-06-24 | — | — | US | disclosed |
| EP-2172471-A2 | A process for preparing intermediates of HMG-CoA reductase inhibitors | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-04-07 | — | — | EP | disclosed |
| US-7687660-B2 | Process for preparing intermediates of HMG-CoA reductase inhibitors | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-03-30 | — | — | US | disclosed |
| EP-2093230-A1 | A process for preparing intermediates of HMG-CoA reductase inhibitors | Teva Pharmaceutical Industries Ltd. (IL) | 2009-08-26 | — | — | EP | disclosed |
| US-20090209779-A1 | Process for preparing intermediates of HMG-CoA reductase inhibitors | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2009-08-20 | — | — | US | disclosed |
| EP-2062903-A1 | Statin intermediates and process for the preparation of statins | Teva Pharmaceutical Industries Ltd. (IL) | 2009-05-27 | — | — | EP | disclosed |
| US-20090076271-A1 | Process for preparing intermediates of HMG-CoA reductase inhibitors | TEVA PHARMACEUTICALS USA, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090076292-A1 | Rosuvastatin intermediates and process for the preparation of rosuvastatin | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2009-03-19 | — | — | US | disclosed |
| EP-2032586-A2 | A PROCESS FOR PREPARING INTERMEDIATES OF HMG-COA REDUCTASE INHIBITORS | Teva Pharmaceutical Industries Ltd. (IL) | 2009-03-11 | — | — | EP | disclosed |
| EP-2032587-A2 | ROSUVASTATIN INTERMEDIATES AND PROCESS FOR THE PREPARATION OF ROSUVASTATIN | Teva Pharmaceutical Industries Ltd. (IL) | 2009-03-11 | — | — | EP | disclosed |
| WO-2008130678-A2 | ROSUVASTATIN INTERMEDIATES AND PROCESS FOR THE PREPARATION OF ROSUVASTATIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130638-A2 | A PROCESS FOR PREPARING INTERMEDIATES OF HMG-COA REDUCTASE INHIBITORS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-10-30 | — | — | WO | disclosed |
| WO-2003087112-A1 | CHIRAL INTERMEDIATE AND PROCESS FOR THE PRODUCTION THEREOF | CLS LABORATORIES, INC. (KR) | 2003-10-23 | — | — | WO | disclosed |
| EP-0168480-A4 | PROCESS FOR PREPARING OPTICALLY-ACTIVE 4-AMINO-3-HYDROXYBUTYRIC ACID. | WISCONSIN ALUMNI RES FOUND (US) | 1987-10-08 | — | — | EP | disclosed |
| US-4584270-A | ENZYME CLEAVAGE OF ESTER GROUPING OF 3-HYDROXYGLUTARIC ACID DIESTER, FOLLOWED BY CHEMICAL CONVERSION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1986-04-22 | — | — | US | disclosed |
| EP-0168480-A1 | PROCESS FOR PREPARING OPTICALLY-ACTIVE 4-AMINO-3-HYDROXYBUTYRIC ACID | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1986-01-22 | — | — | EP | disclosed |
| WO-1985003307-A1 | PROCESS FOR PREPARING OPTICALLY-ACTIVE 4-AMINO-3-HYDROXYBUTYRIC ACID | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1985-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076271-A1 | Process for preparing intermediates of HMG-CoA reductase inhibitors | HMGCR, COASY, PCSK9 | TDP1 3247/4885SMN1; SMN2 4781/4885SLC22A6 2464/4885 |
| US-20100160663-A1 | PROCESS FOR PREPARING INTERMEDIATES OF HMG-CoA REDUCTASE INHIBITORS | HMGCR, COASY, PCSK9 | TDP1 3247/4885SMN1; SMN2 4781/4885SLC22A6 2464/4885 |
| US-20090209779-A1 | Process for preparing intermediates of HMG-CoA reductase inhibitors | HMGCR, COASY, PCSK9 | TDP1 3247/4885SMN1; SMN2 4781/4885SLC22A6 2464/4885 |
| US-20090076292-A1 | Rosuvastatin intermediates and process for the preparation of rosuvastatin | HMGCR, PCSK9, CYP4A11 | TDP1 3354/4885SMN1; SMN2 4571/4885SLC22A6 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.